Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort.


Journal

Rheumatology (Oxford, England)
ISSN: 1462-0332
Titre abrégé: Rheumatology (Oxford)
Pays: England
ID NLM: 100883501

Informations de publication

Date de publication:
01 03 2020
Historique:
received: 02 03 2019
revised: 07 06 2019
pubmed: 5 8 2019
medline: 1 7 2020
entrez: 5 8 2019
Statut: ppublish

Résumé

Damage in patients with systemic lupus erythematosus is irreversible change in organs due to disease activity, concomitant disease or medication side-effects. It is measured using the Systemic Lupus International Collaborative Clinics Damage Index (SDI) and is associated with increased mortality. Previous reports have suggested associations between damage accrual and various ethnic, disease and treatment factors, but there is a dearth of long-term follow-up data from large multi-ethnic cohorts. We describe a study of damage and mortality in 300 patients from London, UK followed for up to 40 years. We carried out retrospective analysis of medical records and SDI scores of 300 patients followed for up to 40 years (median 13.3 years). Characteristics of the groups who did and did not develop damage and those who died or survived to the end of follow-up were compared using univariable and multivariable analysis. Kaplan-Meier analysis was used to analyse factors affecting mortality and accrual of damage. Damage developed in 231/300 (77%) of patients. There was a linear accrual of damage over 40 years follow-up. Factors associated with damage were African/Caribbean ethnicity, renal and cerebral involvement, early use of high-dose corticosteroids or immunosuppressants, anti-RNP and antiphospholipid antibodies. Damage was strongly associated with mortality. Of 87 patients who died, 93% had damage compared with 70% of survivors (P < 0.001). Development of damage is strongly associated with increased mortality. We identified groups at increased risk of developing damage, including those treated with high-dose steroids and immunosuppressants within the first two years.

Identifiants

pubmed: 31377781
pii: 5543448
doi: 10.1093/rheumatology/kez292
pmc: PMC8414923
doi:

Substances chimiques

Adrenal Cortex Hormones 0
Immunosuppressive Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

524-533

Subventions

Organisme : Versus Arthritis
ID : 21992
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/P017371/1
Pays : United Kingdom

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Rheumatology.

Références

Lupus. 2006;15(5):285-91
pubmed: 16761503
Lupus. 2018 Apr;27(5):864-869
pubmed: 29308727
Lupus Sci Med. 2015 Mar 11;2(1):e000066
pubmed: 25861455
Lupus. 2018 Oct;27(12):1989-1995
pubmed: 30092732
PLoS One. 2016 Nov 15;11(11):e0166270
pubmed: 27846298
Arthritis Rheum. 2012 Dec;64(12):4021-8
pubmed: 22932985
Rheumatology (Oxford). 2009 May;48(5):542-5
pubmed: 19233884
Rheumatology (Oxford). 2012 Mar;51(3):491-8
pubmed: 22109798
Semin Arthritis Rheum. 2013 Dec;43(3):352-61
pubmed: 23786872
Rheumatology (Oxford). 2016 Jul;55(7):1243-50
pubmed: 27018057
Lupus. 2017 Oct;26(11):1197-1204
pubmed: 28420047
Rheumatology (Oxford). 2015 May;54(5):836-43
pubmed: 25323056
Rheumatology (Oxford). 2017 Jan;56(1):121-128
pubmed: 27803306
Lupus. 2015 Mar;24(3):256-62
pubmed: 25318970
Nat Rev Rheumatol. 2013 May;9(5):301-10
pubmed: 23229448
Arthritis Rheum. 2001 Dec;44(12):2797-806
pubmed: 11762940
Medicine (Baltimore). 2006 May;85(3):147-156
pubmed: 16721257
Lupus. 2016 Jun;25(7):719-26
pubmed: 26821965
Arthritis Rheum. 2007 Feb;56(2):622-30
pubmed: 17265497
Arthritis Res Ther. 2016 Nov 9;18(1):260
pubmed: 27829463
J Rheumatol. 2009 Mar;36(3):560-4
pubmed: 19208608
Lupus. 2013 Oct;22(12):1214-24
pubmed: 24097993
Rheumatology (Oxford). 2009 Jun;48(6):673-5
pubmed: 19359343
Lupus. 2010 Jul;19(8):949-56
pubmed: 20375124
Arthritis Rheum. 2005 May;52(5):1473-80
pubmed: 15880829
Lupus. 2001;10(2):93-6
pubmed: 11237132
Arthritis Rheum. 1996 Mar;39(3):363-9
pubmed: 8607884
Clin Exp Nephrol. 2018 Jun;22(3):597-602
pubmed: 29071504
J Rheumatol. 2003 Sep;30(9):1955-9
pubmed: 12966597
Ann Rheum Dis. 2015 Sep;74(9):1706-13
pubmed: 24834926
Arthritis Rheum. 2004 Oct;50(10):3177-86
pubmed: 15476246

Auteurs

Beatriz Tejera Segura (BT)

Centre for Rheumatology Research, Division of Medicine, University College London, London, UK.

Brett Sydney Bernstein (BS)

Centre for Rheumatology Research, Division of Medicine, University College London, London, UK.

Thomas McDonnell (T)

Centre for Rheumatology Research, Division of Medicine, University College London, London, UK.

Chris Wincup (C)

Centre for Rheumatology Research, Division of Medicine, University College London, London, UK.

Vera M Ripoll (V)

Centre for Rheumatology Research, Division of Medicine, University College London, London, UK.

Ian Giles (I)

Centre for Rheumatology Research, Division of Medicine, University College London, London, UK.

David Isenberg (D)

Centre for Rheumatology Research, Division of Medicine, University College London, London, UK.

Anisur Rahman (A)

Centre for Rheumatology Research, Division of Medicine, University College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH